Skip to content

Hyperinflation in COPD exacerbations

Hyperinflation in COPD exacerbations - Hyperinflation in COPD exacerbations

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON40607
Enrollment
30
Registered
2014-05-16
Start date
2014-09-18
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease COPD lung emfysema and chronic bronchitis

Interventions

None listed

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Male or Female, 40 years or older Doctor*s diagnosis of COPD. Experiencing an exacerbation of COPD requiring hospitalization at the moment of inclusion. An exacerbation is defined as a worsening of respiratory symptoms from the stable state and beyond normal day-to-day variations, which requires additional treatment. Patients must be able to understand and complete protocol requirements, Instructions and questionnaires in Dutch Written Informed consent

Exclusion criteria

Exclusion criteria: If any of these criteria are absent at admission, but occur during the course of the study, patients will be followed up within the protocol as much as possible. Pneumonia confirmed with X ray COPD exacerbation requiring (non) invasive ventilation or admittance to an intensive care unit Patient who received any investigational new drug within the last 4 weeks prior to admission or twice the duration of the biological half-life of any investigational new drug (whichever is longer). Unstable angina pectoris or other clinically important cardiac co-morbidity requiring admission on a cardiology ward

Design outcomes

Primary

MeasureTime frame
Temporal relation between changes in hyperinflation (as measured by inspiratory capacity) during resolution of the exacerbation, and changes in HR-QoL and dyspnoea.

Secondary

MeasureTime frame
Other HR-QoL and dyspnea patient report outcomes (PRO)'s Lung function parameters: dynamic hyperinflation, TLC, diffusion, FEV1, FVC, IOS, single breath nitrogen washout. Enose for measurement of exhaled organic compounds Inflammation parameters measured by blood sample and nasopharyngeal swab Infection as assessed by routine lab and cultures Length of stay in the hospital

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)